Trials / Completed
CompletedNCT00511940
Acamprosate in the Treatment of Binge-Eating Disorder
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Lindner Center of HOPE · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | acamprosate | 999 mg/day - 2997 mg/day, oral |
| OTHER | placebo | oral, placebo |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2007-08-06
- Last updated
- 2011-06-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00511940. Inclusion in this directory is not an endorsement.